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Edited by Varda RotterAbstract Here, we report the construction and functional anal-
ysis of synthetic promoters designed for gene therapy applica-
tions requiring strong and speciﬁc gene expression in
melanoma cell lines. We have analysed the transcriptional activ-
ity of diﬀerent combinations of two transcriptional regulatory
modules, a melanocyte-speciﬁc element from the human tyrosi-
nase promoter and a cell-cycle-speciﬁc element from the human
a-fetoprotein promoter. Transient expression assays in diﬀerent
cell lines show that several of these composite synthetic promot-
ers can drive a strong and selective expression of a reporter gene
in melanoma cell, providing us with a new powerful tool for gene
therapy of melanomas.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Melanoma is a highly aggressive tumour and eﬀective thera-
peutic agents are not currently available, therefore gene ther-
apy represents a promising approach for the treatment of
this disease. Several strategies have been developed for gene
therapy of cancer and many eﬀorts have been directed to the
construction of transcriptionally targeted vectors to obtain
the expression of cytotoxic genes in a tumour-speciﬁc manner,
avoiding non-speciﬁc toxicity [1–4].
Tumour-cell-speciﬁc expression can be achieved by the use
of a tumour-speciﬁc promoter. The majority of melanoma cells
synthesise melanin, and the rate-limiting step of this metabolic
pathway is the hydroxylation of tyrosine catalysed by the en-
zyme tyrosinase [5]. Tyrosinase is the key enzyme in melano-
genesis and it is expressed in a tissue-speciﬁc manner in
pigmented cells, including melanoma [6].
Transcriptional regulatory elements that are crucial for the
expression and the tissue-speciﬁcity of the tyrosinase gene have
been identiﬁed and characterised [7,8]. The human tyrosinase
proximal promoter is regulated by one negative and four posi-
tive elements. There are no data on the identity of the factors
involved in the negative regulation. The positive elements con-
tain a binding site for the SP1 transcription factor, a highly
conserved M-box, a CR2 element containing the initiator E*Corresponding author. Fax: +39 081 7463074.
E-mail address: desimone@dbbm.unina.it (V. De Simone).
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.11.068box and an octamer element. The M-box is associated in the
activation of tyrosinase gene expression through the product
of microphthalmia gene (Mi), which is known to be involved
in melanocyte diﬀerentiation [9]. In addition to the proximal
promoter region, a strong and cell-speciﬁc expression of the
tyrosinase gene requires an enhancer element located 2 kb up-
stream of the transcriptional start site, containing a tyrosinase
distal element (TDE) which enhances tissue-speciﬁcity through
the binding of Mi [10]. This is in line with the general organi-
zation of eukaryotic promoters, in which the tissue-speciﬁcity
is achieved through the cooperation of multiple elements usu-
ally located at considerable distance from one another.
Several attempts have been made to use tyrosinase promoter
and enhancer elements in vectors for melanoma gene therapy
[11–16]. However, viral vectors employing long promoter se-
quences, although able to drive-speciﬁc gene expression, often
display a reduction in viral titre that correlates with the size of
the inserted promoter [12]. Furthermore, many vectors have a
size-constrain that does not allow the insertion of a full pro-
moter. On the other hand, shorter promoter sequences are of-
ten too weak or lose speciﬁcity. Therefore, the availability of
compact and highly speciﬁc promoters will multiply the possi-
ble gene therapy approaches to melanoma.
In this context, we developed a strategy for the construction
of compact synthetic promoters to be utilised in melanoma
gene therapy. We have previously found that the polymerisa-
tion of a 100 nucleotides region of the human a-fetoprotein
proximal promoter, a combination of an AP1/GRE (cell-cycle
speciﬁc) and a HNF1 (liver speciﬁc) regulatory elements, is
very eﬀective for the production of synthetic promoters with
a high hepatoma-speciﬁcity (our unpublished results). Here,
we describe the construction and analysis of synthetic promot-
ers containing diﬀerent combinations of the human tyrosinase
promoter M-box and of the previously described AP1/GRE
transcriptional elements. Transient expression assays in diﬀer-
ent cell lines show that these synthetic promoters can drive a
strong expression of a CAT reporter gene selectively in mela-
noma cell, providing us with a new powerful tool for gene ther-
apy of melanomas.2. Materials and methods
2.1. Cell culture and cell lines
The human cell lines MeWo and A2058 (melanoma), Hela and the
murine melanoma cell line B16, were obtained from American Type
Culture Collection (Manassas VA, USA). All cells were cultured in
DMEM supplemented with 10% FBS, 2 mM glutamine, 50 IU/ml pen-
icillin, and 50 lg/ml streptomycin in a 5% CO2, 37 C.blished by Elsevier B.V. All rights reserved.
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Cells were transfected with 20 lg of plasmid DNA using N 0,N-bis(2-
hydroxyethylpiperazine)-2-aminoethanesulfonic acid method [17] with
some modiﬁcations. Transfections were carried out overnight at 3%
CO2 and 35 Cand followed by a 3min 10%glycerol shock. After a three
times rinse with PBS, cells were reefed and incubated at 5% CO2, 37 C.
CAT assays were performed 48 h after transfections using the CATELI-
SA colorimetric immunoassay (ROCHE) as described by the manufac-
turer. To normalise the transfection eﬃciency among the samples of
the same experiment, the test plasmids were cotransfected with a cyto-
megalovirus (CMV)-luciferase reporter construct. All transfectionswere
repeated at least three times and with diﬀerent plasmid preparations. In
order to compare the results obtained in diﬀerent cell lines, the data re-
ported in Fig. 2 have been further normalised by dividing them for the
positive control values (pSV2-CAT) obtained in that speciﬁc cell line.
2.3. Construction of promoter-reporter vectors
The CAT constructs for the analysis of synthetic promoters are
based on the expression vectors pTKshortCAT and EI2XCAT [18].
Two complementary oligonucleotides containing the M-box and the
functional binding sites for AP1 and GRE were phosphorylated at 5 0
termini using T4 polynucleotide kinase, annealed and ligated to form
concatenamers. The ends of ligated products were ﬁlled-in by using
the Kleenow fragment of Escherichia coli DNA polymerase I and
cloned into pTKshortCAT. The oligonucleotides containing the
TDE elements were phosphorylated, annealed and ligated as described
before. Plasmids were propagated in E. coli strain DH5a and analysed
by restriction mapping and DNA sequencing.
3. Results
We designed two complementary synthetic oligonucleotides
containing the tissue-speciﬁc M-box of the human tyrosinaseFig. 1. Architecture of our synthetic Ty promoters. The topside is
toward the reporter gene.
Fig. 2. Transient expression assays of Ty constructs in human (A2058, MeW
the ratio between the absolute value and the positive control value (pSV2-Cgene, associated to the AP1 and GRE cell-cycle-speciﬁc ele-
ments (Section 2). The oligonucleotides were multimerised,
cloned randomly in the expression vector pTKshortCAT [18]
and recombinant clones containing diﬀerent copies and combi-
nations of these regulatory elements were selected. The sche-
matic structure of the diﬀerent promoters is illustrated in
Fig. 1.
The transcriptional eﬃciency and speciﬁcity of these diﬀer-
ent combinations were analysed by transient expression in
three diﬀerent melanoma cell lines (B16, MeWo and A2058)
and in Hela cells as control (Fig. 2). Quantisation of CAT
activity demonstrated that single copies of the M-box and
AP1 elements, either alone or together, make very poor pro-
moters. However, the addition to the M-box and AP1 of a sin-
gle GRE element (compare 3Ty with 31Ty) results in a
signiﬁcant increase of transcriptional activity in mouse mela-
noma cells (B16) and in human melanoma cells (MeWo), while
it is completely ineﬀective in the highly metastatic human mel-
anoma cell line A2058. This combination of elements cannot
be considered cell-speciﬁc, since the transcriptional activity ob-
served in Hela cells is comparable to that observed in B16 mel-
anoma cell lines (see also construct 31-Ty in Fig. 3).
The 7-Ty promoter, containing 3 GRE, 3 AP1 and 2 M-box,
appears to be the most eﬀective and speciﬁc combination in
melanoma cells. The comparison of CAT activity of 7-Ty
and pSV2CAT clearly shows that in melanoma cells the 7-Ty
promoter is stronger than pSV2CAT. A further increase of
the number of regulatory elements may result in a loss of spec-
iﬁcity, as evident for recombinant 20-Ty, whose expression in
HeLa cells increases as compared to 7-Ty.
The use of a synthetic enhancer element containing three
copies of the tyrosinase distal enhancer (TDE) has been re-
ported to generate transcriptionally targeted vectors for gene
therapy of melanoma [13]. Therefore, we decided to compare
the eﬃciency and cell-speciﬁcity of this synthetic enhancer
to those of our promoters. A synthetic oligonucleotide con-
taining three copies of TDE element was subcloned in both
orientations in pTKshortCAT. We also generated a recombi-
nant clone containing six copies of TDE element. Fig. 3 shows
that, in melanoma cells, our synthetic promoters are more eﬃ-o) and murine (B16) melanoma cell lines. CAT activity is expressed as
AT).
Fig. 3. Comparison of Ty and TDE constructs transient expression in
B16 melanoma and in HeLa cell lines. TDE, trimer of the Tyrosinase
Distal Enhancer; TDE 2X, further dimerisation of TDE.
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their expression is lower in non-melanoma cells. These results
suggest that our promoters may be better suitable to drive mel-
anoma-speciﬁc expression of a therapeutic gene.4. Discussion
A main problem of gene therapy approaches is how to target
a speciﬁc tissue or a group of cells within the whole organism,
leaving the other tissues unaﬀected. Virus-derived vectors may
take advantage of natural viral tropism or, alternatively, the
viral molecules involved in the cell entry pathway can be mod-
iﬁed to redirect a virus toward a diﬀerent host. However, the
availability of naturally host-restricted vectors is limited to a
minority of cell types, e.g., lymphocytes or neural cells. More-
over, despite the huge eﬀorts of several research groups,
manipulation of the viral entry mechanisms almost invariably
results in a marked reduction of infection eﬃciency and/or
virus stability.
A relatively easier way to obtain selectivity is to use tissue or
cell-speciﬁc transcription regulatory signals to drive the
expression of the therapeutic gene. In this case, even if the vec-
tor can infect diﬀerent cell types, the infection will result in the
expression of the therapeutic gene only in the desired cell type.
This result can be achieved by incorporating in gene therapy
vectors natural tissue-speciﬁc promoters, and there are several
reports in which this approach has been successfully employed
[12–16].
Nevertheless, Pol II promoters are often very large and com-
plex, and tissue-speciﬁc transcription results from the combi-
natory co-operation of several control elements, each of
them contributing only partially to speciﬁcity, spread over very
large DNA fragments. On the other hand, in the most widely
used vectors for gene therapy space constrains prevent the
incorporation of very large promoter region and impose to
use only part of them, thus reducing transcriptional eﬃciency
and speciﬁcity.
The majority of gene therapy approaches to melanomas are
currently based on selective expression in melanoma cells of a
variety of therapeutic genes: ‘‘suicide’’ genes, tumour suppres-
sor genes, inhibitors of aberrant oncogene expression, or
genes encoding immunologically relevant molecules. All ofthese approaches have shown to be eﬀective in vivo, albeit
at diﬀerent degrees and often in combination with other ther-
apeutic protocols [19]. Nevertheless, in all of them the main
issues are the strength and the tightness of the transcriptional
control.
Here, we describe a group of synthetic promoters engineered
to obtain high levels of melanoma-speciﬁc expression, the lar-
ger of them not exceeding 300 nucleotides. These promoters
are strong enough to achieve in melanoma cells transcriptional
levels higher than those obtained with the very strong and
compact SV40 enhancer/promoter region, still retaining their
melanoma-speciﬁcity. Experiments to assess the transcrip-
tional activity of these promoter in vivo are in progress.
Our promoters have been speciﬁcally designed to operate in
the context of SV40-derived vectors for a suicide gene ap-
proach. Nevertheless, we believe that these promoters may
be very useful tools for all gene therapy approaches based on
selective expression in melanoma cells, especially when plan-
ning the use of space-limited vectors.
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